Utilizing Long-read Sequencing to Investigate the EGFR Landscape of EGFR Positive Lung Cancer Patients

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexFemale
Age18-100
SponsorOur Lady of the Lake Hospital

About this trial

EGFR gene mutations are some of the most commonly occurring mutations in non-small cell lung cancer. Investigators have developed a DNA instability model that estimates a risk score to assess the likelihood of an individual acquiring a cancer-linked mutation. The aim of this study is to collect blood from both those diagnosed with EGFR positive lung cancer and healthy individuals, evaluate their gene sequence surrounding the EGFR landscape and use the cancer positive and healthy sequences to validate the risk assessment model, which may one day be used to provide insight on susceptibility of getting EGFR positive lung cancer or potentially other cancer types.

Eligibility criteria

Qualifiers

18-100 years old

Biologically born female

Diagnosed with EGFR positive lung cancer (Arm 1-Cancer group)

No cancer diagnosis (Arm 2-health control)

Disqualifiers

less than 18 years of age

Biologically born male

Incarcerated at the time of participation

Trial design

Treatments tested in this trial

  • blood draw
  • Gene sequencing

Treatment groups

20 Participants
are divided into 2 treatment groups

Sponsors and collaborators